Yousuf Zafar (@yzafar), MD, GI oncologist and associate professor of medicine, Duke University, highlights perspectives that are missing from the “general rubric” of value-based care in oncology, how real-world evidence (RWE) can help augment takeaways from clinical trial data, issues of capturing the patient voice in real-world data and electronic health records, and how the FDA is utilizing RWE for expanding drug indications. Dr. Zafar shares where he sees the intersection between RWE and value-based care existing from a payer perspective as well why he believes the COVID-19 pandemic provides “fertile ground” for the prevalence of RWE.
Podden och tillhörande omslagsbild på den här sidan tillhör Chadi Nabhan. Innehållet i podden är skapat av Chadi Nabhan och inte av, eller tillsammans med, Poddtoppen.
